Market Cap | 49.98M | P/E | - | EPS this Y | -80.60% | Ern Qtrly Grth | - |
Income | -8.12M | Forward P/E | -1.09 | EPS next Y | -20.90% | 50D Avg Chg | 23.00% |
Sales | 57.31M | PEG | -0.17 | EPS past 5Y | - | 200D Avg Chg | 29.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | 3.20% | 52W High Chg | -37.00% |
Recommedations | 2.00 | Quick Ratio | 0.68 | Shares Outstanding | 6.58M | 52W Low Chg | 100.00% |
Insider Own | 3.96% | ROA | -9.84% | Shares Float | 3.90M | Beta | 1.10 |
Inst Own | 58.79% | ROE | - | Shares Shorted/Prior | 205.63K/27.30K | Price | 0.62 |
Gross Margin | 14.71% | Profit Margin | -14.18% | Avg. Volume | 207,909 | Target Price | 16.50 |
Oper. Margin | -76.55% | Earnings Date | May 13 | Volume | 233,401 | Change | 4.73% |
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
BIOTECH TARGET N V | Director Director | Jul 17 | Buy | 0.470 | 4,255,319 | 2,000,000 | 15,447,322 | 07/19/23 |
Kim Jason S. | See remarks See remarks | Jul 07 | Option | 0.71 | 12,089 | 8,583 | 95,493 | 07/11/22 |
LALANDE KEVIN M. | Director Director | Jun 13 | Buy | 0.89 | 222,000 | 197,580 | 222,000 | 06/21/22 |
SHV Management Services, LLC | 10% Owner 10% Owner | Jun 13 | Buy | 0.89 | 222,000 | 197,580 | 222,000 | 06/21/22 |
McLennan Sean | See remarks See remarks | Jun 16 | Buy | 0.8159 | 30,000 | 24,477 | 30,000 | 06/21/22 |
BIOTECH TARGET N V | 10% Owner 10% Owner | May 16 | Buy | 1.181 | 200,000 | 236,200 | 11,192,003 | 05/18/22 |
Poma Eric E | See remarks See remarks | Apr 27 | Option | 0.71 | 34,156 | 24,251 | 277,615 | 04/29/22 |
BIOTECH TARGET N V | 10% Owner 10% Owner | Jan 06 | Buy | 4.0359 | 200,000 | 807,180 | 10,992,003 | 01/10/22 |